Hansa announces first patient dosed with imlifidase in a global pivotal phase 3 trial in anti-glomerular basement membrane (anti-GBM) disease ...Middle East

LUND, Sweden, May 30, 2023 /PRNewswire/ -- Hansa Biopharma ("Hansa"), a pioneer in enzyme technology for rare immunological conditions, today announced the first patient has been dosed with imlifidase in the GOOD-IDES-02 trial, a global pivotal phase 3 trial in anti-glomerular basement...

Read More Details
Finally We wish PressBee provided you with enough information of ( Hansa announces first patient dosed with imlifidase in a global pivotal phase 3 trial in anti-glomerular basement membrane (anti-GBM) disease )

Also on site :

• Barbra Streisand Reveals Jaw-Dropping Details of Scandalous Proposal from Hollywood Icon!
• Today’s NYT ‘Strands’ Hints, Spangram and Answers for Tuesday, June 17
• Global South feels strong desire for change in the world order - Indian Foreign Minister